Drugs / amezosvatein
amezosvatein
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05304351 | Feb 2022 → Jun 2026 overdue | herpes zoster | Curevo Inc | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | amezosvatein | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05304351 ↗ |
| Known as | Amezosvateina | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068202 ↗ |
| Known as | Amezosvateine | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068202 ↗ |
| Known as | CRV-101 | “The purpose of this study is to assess the safety and immunogenicity of amezosvatein (CRV-101), an investigational vaccine compared to Shingrix® for the prevention of herpes...” NCT05304351 ↗ |
| Modality | Vaccine | “amezosvatein (CRV-101), an investigational vaccine” NCT05304351 ↗ |
| Route | Intramuscular | “administered intramuscularly (IM) in the deltoid region of the non-dominant arm” NCT05304351 ↗ |